The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Jazz Pharmaceuticals plc recently disclosed its financial update and corporate overview at the J.P. Morgan Healthcare ...

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...

Speaking at the JP Morgan Healthcare Conference 2025 yesterday (14 January), Cozadd said: “We’ve got some really exciting ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings ...

Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing ...

New genetic risk factors for depression have been identified across all major global populations for the first time, allowing scientists to predict risk of depression regardless of ethnicity.

Researchers from the University of Edinburgh and King’s College London believe the findings offer new insight into the ...

Depression is a highly prevalent disorder, and researchers still have a lot to learn about its biological underpinnings.

New genetic risk factors for depression have been identified across all major global populations for the first time, allowing scientists to predict risk of depression regardless of ethnicity. The ...